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Abstract
Hsulf-1 is a newly identified enzyme, which has the ability to decrease the growth of hepatocellular,
ovarian, and head and neck squamous cell carcinoma cells by interfering with heparin-binding
growth factor signaling. Since pancreatic cancers over-express a number of heparin-binding growth
factors and their receptors, the expression and function of this enzyme in pancreatic cancer was
analyzed.
Results: Pancreatic cancer samples expressed significantly (22.5-fold) increased Hsulf-1 mRNA
levels compared to normal controls, and Hsulf-1 mRNA was localized in the cancer cells
themselves as well as in peritumoral fibroblasts. 4 out of 8 examined pancreatic cancer cell lines
expressed Hsulf-1, whereas its expression was below the level of detection in the other cell lines.
Stable transfection of the Hsulf-1 negative Panc-1 pancreatic cancer cell line with a full length Hsulf-
1 expression vector resulted in increased sulfatase activity and decreased cell-surface heparan-
sulfate proteoglycan (HSPG) sulfation. Hsulf-1 expression reduced both anchorage-dependent and
-independent cell growth and decreased FGF-2 mediated cell growth and invasion in this cell line.
Conclusion: High expression of Hsulf-1 occurs in the stromal elements as well as in the tumor
cells in pancreatic cancer and interferes with heparin-binding growth factor signaling.
Introduction
Pancreatic cancer is one of the most aggressive human
malignancies with an overall five-year survival rate of less
then 5% [1]. Although the reasons for the aggressive
growth behavior of pancreatic cancer are not completely
understood, recent molecular biological studies have
revealed several factors that are involved in the pathogen-
esis of pancreatic cancer. These include genetic changes,
such as k-ras, p53, p16, and Smad4 mutations [2], as well
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as epigenetic alterations, such as overexpression of a
number of growth factors and their receptors [3,4].
Membrane-associated heparin-sulfate proteoglycans
(HSPGs) are thought to play an important role in many
aspects of cellular physiology including growth factor sig-
naling. HSPGs are required for the optimal activity of
heparin-binding growth factors, such as for example
fibroblast growth factors (FGFs) [5,6]. One member of the
HSPG family, glypican-1 is over-expressed in pancreatic
cancer and influences heparin binding growth factor sign-
aling in this disease [7,8]. The heparan-sulfate (HS) chains
of HSPGs seem to interact with the ligands (e.g. FGF-2)
and high-affinity FGF-receptors, to increase ligand-recep-
tor binding and signaling [9]. The enzyme Hsulf-1 is a
recently identified human sulfatase, which exhibits aryl-
sulfatase activity [10]. Hsulf-1 expression is down-regu-
lated in ovarian cancers, and lost in a proportion of liver
cancers [11,12]. Absence or low levels of Hsulf-1 in hepa-
tocellular, ovarian, and head and neck squamous cell car-
cinoma cell lines were associated with up-regulation of
heparin-binding growth factor signaling [11-13]. Since
HSPGs such as glypican-1 play an important role in pan-
creatic cancer and since Hsulf-1 can influence the sulfa-
tion state and the biological function of HSPGs, the
expression and functional role of Hsulf-1 was analyzed in
pancreatic cancer.
Results
Hsulf-1 mRNA expression in pancreatic tissues
Utilizing DNA arrays the expression of nine sulfatase fam-
ily members in pancreatic cancer, pancreatic cancer metas-
tasis, chronic pancreatitis and the normal pancreas was
screened. This analysis revealed that Hsulf-1 was signifi-
cantly over-expressed in pancreatic cancer and chronic
pancreatitis compared to normal pancreatic tissues. Thus,
Hsulf-1 mRNA expression levels were increased 9.1-fold
in primary pancreatic cancer, 4.5-fold in pancreatic cancer
metastasis, and 3.4-fold in CP tissues compared to normal
pancreatic tissues. In contrast, there were only minor or
no changes in the mRNA levels of the other members of
the sulfatase family (Table 1). In order to better quantify
Hsulf-1 expression quantitative RT-PCR was carried out in
normal pancreatic tissue samples (n = 19), chronic pan-
creatitis (n = 22) and pancreatic cancer tissue samples (n
= 31). The samples from normal tissues had a mean (+/-
SEM) number of Hsulf-1 transcripts/µl of 114 ± 23, while
Hsulf-1 mRNA levels increased in both chronic pancreati-
tis and pancreatic cancer, with mean (+/- SEM) transcripts
levels of 2054 ± 911 in chronic pancreatitis and 2566 ±
420 in pancreatic cancer. 10 of 22 (45%) CP and 22 of 31
(71%) pancreatic cancer tissue samples displayed higher
copy numbers of Hsulf-1 mRNA than the highest Hsulf-1
mRNA level observed in normal pancreatic tissue samples
(Figure 1).
Localization of Hsulf-1 in pancreatic tissues
To identify the local expression pattern of Hsulf-1 in the
normal pancreas, chronic pancreatitis and pancreatic can-
cer tissues, in situ hybridization analysis was carried out.
Weak Hsulf-1 mRNA expression was observed in the acini
of normal and chronic pancreatitis tissues. Hsulf-1 mRNA
was localized in the smooth muscle cells and the endothe-
lium of blood vessels, as well as in fibroblasts of the con-
nective tissue (Figure 2 A–C). In addition, Hsulf-1 mRNA
expression was present in tubular complexes of chronic
pancreatitis tissues (Figure 2 D). In pancreatic cancer tis-
sues, Hsulf-1 mRNA was mainly expressed in tubular
complexes (Figure 2 E), in the cancer cells themselves
(Figure 2 F, G) as well as in fibroblasts of the connective
tissue (Figure 2 F).
Hsulf-1 expression in pancreatic cancer cell lines
QRT-PCR analysis was carried out in 8 cultured pancreatic
cancer cell lines. This analysis revealed relatively high
expression of Hsulf-1 mRNA in Su-8686 and moderate
Table 1: Expression of different sulfatases in normal pancreas (No), chronic pancreatitis (CP), primary pancreatic cancer (CA) and 
pancreatic cancer metastasis (Mx) tissues as determined by DNA array analysis.
Fold change
Ca vs No Mx vs No CP vs No
hSulf-1 9.1 4.5 3.4
Arylsulfatase A 0.6 0.8 0.9
Arylsulfatase B 1.8 1.6 1.8
Arylsulfatase C 1.6 1.8 1.6
Arylsulfatase D 0.5 0.2 0.8
Arylsulfatase E 0.5 0.6 0.7
galactosamine (N-acetyl)-6-sulfate sulfatase 0.8 0.8 0.9
glucosamine (N-acetyl)-6-sulfatase 2.5 2.2 1.6
iduronate 2-sulfatase 1.0 1.2 1.0Molecular Cancer 2005, 4:14 http://www.molecular-cancer.com/content/4/1/14
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expression in T3M4, Colo-357, and BxPc-3 pancreatic
cancer cell lines. In the other cell lines, Hsulf-1 expression
was below the detection level (Figure 3 A). Panc-1 pancre-
atic cancer cells were selected for Hsulf-1 transfection,
since Hsulf-1 expression was below the level of detection
in this cell line. To confirm successful transfection of
Panc-1 cells with the full-length Hsulf-1 construct, North-
ern blot analysis was carried out using a Hsulf-1 antisense
riboprobe. A total of number 36 clones were screened, of
which 10 clones clearly expressed Hsulf-1 mRNA. Two
Hsulf-1 positive clones (sulf-26 and sulf-38) were selected
for use in further experiments and compared to empty
vector-transfected (EV) and non transfected wild type
(WT) Panc-1 cells (Figure 3 B). To confirm the expression
of Hsulf-1 in the positive clones on the protein level,
immunoblotting was performed. Since the Hsulf-1
expression plasmid contained a c-myc tag [10], it was pos-
sible to detect the expression of the Hsulf-1-myc fusion
protein in the selected clones by immunoblot analysis
with an anti-c-myc antibody (Figure 3 C). To determine
the activity of the expressed sulfatase, cellular extracts pre-
pared from both control (wild type and empty vector) and
transfected clones (sulf-26, sulf-38) were analyzed. 4-
Methylumbelliferyl-sulfate, which represents a substrate
for a variety of sulfatases, including cellular steroid
sulfatases, was used as the substrate for sulfatase activity.
Upon transfection, sulfatase activity was most promi-
nently increased in clone sulf-38 (Figure 3 D). However,
since this assay could not differentiate between different
sulfatases, high sulfatase activity was also observed in the
control cells. Therefore, to further confirm successful
transfection and increased Hsulf-1 activity, immunofluo-
rescence with the 10E4 anti-HSPG monoclonal antibody,
which recognizes N-sulfated glucosamine-containing
HSPGs, was carried out. Prominent staining of the cell
membrane was observed in both wild type (Figure 4A)
and empty vector Panc-1 cells (Figure 4 C). In contrast,
markedly diminished staining of the cell membrane was
observed in the two Hsulf-1 expressing clones (Figure 4 B,
D), indicating that Hsulf-1 desulfates HSPGs at the cell
surface.
Functional consequences of Hsulf-1 expression in Panc-1 
pancreatic cancer cells
Next, the effects of Hsulf-1 expression on the growth of
Panc-1 cells were assessed. Analysis of basal growth
revealed that the 2 control clones displayed an average
exponential doubling time of 50.3 ± 3.2 hours, which was
significantly shorter compared to the 2 Hsulf-1 transfected
clones (68.2 ± 4.3 hours) (Figure 5 A). To determine
anchorage-independent growth rates, soft agar assays
were carried out. The 2 control clones showed an average
colony number of 223 as compared to 31 colonies for the
Hsulf-1 transfected cells (Figure 5 B).
Hsulf-1 decreases FGF-2 mediated cell proliferation and 
signaling in Panc-1 pancreatic cancer cells
It has been shown previously that a variety of growth fac-
tors such as FGF-2, EGF, HB-EGF, and IGF-1 are over
expressed in pancreatic cancer and that they have the
potential to act as mitogens for pancreatic cancer cell lines
[3,4]. Therefore, we further investigated whether over-
expression of Hsulf-1 could modulate the function of
these growth factors in pancreatic cancer cells. Two Hsulf-
1 transfected clones and two controls (wild type and
empty vector) were selected to perform growth assays in
the presence or absence of different doses of the indicated
growth factors. Hsulf-1 expression significantly attenu-
ated FGF-2 (50 ng/ml) induced cell growth by around
50%, from +28.0 ± 3.8% in controls to +14.4 ± 1.0 % in
Hsulf-1 clones (Figure 6). In contrast, there was no
difference in the response towards IGF-1, EGF or HB-EGF
in the control versus Hsulf-1 expressing cells. Since Hsulf-
1 expression reduced FGF-2 but not EGF or HB-EGF
induced cell proliferation, next we sought to investigate
whether Hsulf-1 expression would influence FGF-2 and
EGF/HB-EGF downstream signaling. EGFR phosphoryla-
tion was not changed in response to EGF or HB-EGF in
Hsulf-1 expressing clones compared to controls (Figure 7
A). In addition, there was also no difference of EGF and
HB-EGF induced MAPK phosphorylation between control
cells and positive clones (Figure 7 A). In contrast, control
cells showed increased MAPK phosphorylation after FGF-
2 stimulation, while this FGF-2 induced phosphorylation
Expression of Hsulf-1 mRNA in pancreatic tissues and cell  lines Figure 1
Expression of Hsulf-1 mRNA in pancreatic tissues 
and cell lines Quantification of Hsuf-1 mRNA levels in the 
normal pancreas, chronic pancreatitis (CP), pancreatic can-
cer tissues (PC), by real time QRT-PCR as described in the 
Material and Methods section. Values are normalized to 
housekeeping genes (cyclophilin B and HRPT), and presented 
as single values and mean (horizontal line).
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Expression and localization of Hsulf-1 mRNA in pancreatic tissues Figure 2
Expression and localization of Hsulf-1 mRNA in pancreatic tissues In situ hybridization was performed as described in 
Material and Methods section. Hsulf-1 localization in: normal pancreatic acini (A); blood vessels (B), nerves (C), and tubular 
complexes (D) of CP; tubular complexes (E), cancer cells (F) of pancreatic cancer. Note the staining in the control section 
probed with the antisense riboprobe (G), compared with absent staining in the sense-probed section (H).
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Expression of Hsulf-1 in pancreatic cancer cell lines Figure 3
Expression of Hsulf-1 in pancreatic cancer cell lines (A) Quantification of Hsulf-1 mRNA levels in pancreatic cancer cell 
lines by real time QRT-PCR as described in the Materials and Methods section. Values are normalized to housekeeping genes 
(cyclopilin B and HRPT), and presented as mean ± SD. (B/C) Panc-1 cells were stable transfected with a Hsulf-1 sense expres-
sion plasmid as described in the Material and Methods section. (B) Hsulf-1 sense RNA expression in Panc-1 cells was verified by 
Northern blot analysis using a radiolabeled Hsulf-1 antisense riboprobe. A sample Northern blot of 2 controls and 2 trans-
fected clones is shown. (C) Expression of c-myc tagged Hsulf-1 (arrow) by immunoblot analysis as described in the Materials 
and Methods section. Equal loading of the protein samples was confirmed using anti-γ -tubulin antibodies. (D) Sulfatase activity 
was measured as described in Material and Methods section in control and positive transfected clones. Data are expressed as 
relative fluorescence and presented as mean ± SD.
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was markedly attenuated in Hsulf-1 transfected cells (Fig-
ure 7 B). Next, the basal and FGF-2 induced invasion
capacity of tumor cells was analyzed. This analysis
revealed a significant reduction in the invasiveness of
FGF-2 exposed Hsulf-1 expressing cells compared to
Hsulf-1 negative clones. As demonstrated in Figure 7C,
FGF-2 (10 µg/ml) significantly stimulated the invasion of
the control cells by +83.4 ± 24.2% after 24 h of incuba-
tion. In contrast, the invasion ability of Hsulf-1 positive
cells was significantly less stimulated (+27.4 ± 35.5%) by
exposure to FGF-2 (Figure 7 C).
Effects of Hsulf-1 expression on chemosensitivity
Pancreatic cancers exhibit variable degrees of chemother-
apy resistance. To determine whether Hsulf-1 expression
might influence the sensitivity of Panc-1 cells to chemo-
therapeutic agents, cells were treated with gemcitabine, 5-
FU, or actinomycin-D and the GI50 concentration was
calculated. The GI50 concentration of gemcitabine in the
Panc-1 WT control cells was 3.9 nM, and in EV Panc-1
cells approximately 50 nM. Interestingly Hsulf-1 express-
ing cells exhibited GI50 values of more than 100 nM
(Figure 8). In contrast no significant changes were
Hsulf-1 decreases the sulfation of cell surface HSPGs Figure 4
Hsulf-1 decreases the sulfation of cell surface HSPGs Immunofluorescence was performed as described in Material and 
Methods section with a specific 10E4 anti-HSPG monoclonal antibody, which recognizes native heparan-sulfate containing the 
N-sulfated glucosamine moiety. WT (A), EV (C), Sulf-26 (B), Sulf-38 (D).
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Hsulf-1 expression decreases Panc-1 pancreatic cancer cell growth Figure 5
Hsulf-1 expression decreases Panc-1 pancreatic cancer cell growth (A) Basal cell growth as determined by the MTT 
assay. Data are expressed as mean ± SD of three independent experiments. Data are presented for control cells (WT, EV), as 
well as for Hsulf-1 transfected clones. (Sulf-26, Sulf-38). (B) Anchorage-independent cell growth for individual clones was 
measured by the soft agar assay as described in the Material and Methods section. Data are presented for controls and positive 
clones as indicated. Data are presented as mean ± SEM obtained from three independent experiments.
c
e
l
l
g
r
o
w
t
h
 
(
f
o
l
d
i
n
c
r
e
a
s
e
)
A
1 2 3 4 5 6 7
1
2
3
4
5
6
WT
EV
Sulf-26
Sulf-38
0
50
100
150
200
250
300
350
W
T
E
V
S
u
l
f
-
2
6
S
u
l
f
-
3
8
c
o
l
o
n
y
n
u
m
b
e
r
s
B
daysMolecular Cancer 2005, 4:14 http://www.molecular-cancer.com/content/4/1/14
Page 8 of 14
(page number not for citation purposes)
observed in the sensitivity of Hsulf-1 positive clones and
control cells towards 5-FU and actinomycin-D.
Discussion
Sulfatases are a family of enzymes that catalyse the hydrol-
ysis of sulfate ester bonds from a wide variety of com-
pounds. They are classified into arylsulfatases and
nonarysulfatases according to their ability to hydrolyse
the sulfate ester bonds of aromatic compounds such as p-
nitrocatechol sulfate and 4-methylumbelliferyl sulfate
[14]. Hsulf-1 is a newly identified member of the sulfatase
family, which exhibits arysulfatase activity and removes
sulfate from the C-6 position of glucosamine within the
specific sub regions of intact heparin [10]. In the present
Effects of Hsulf-1 expression on growth factor induced proliferation Figure 6
Effects of Hsulf-1 expression on growth factor induced proliferation. Clones were cultured in 1% FBS medium and 
incubated with increasing concentrations of the indicated growth factors for 72 h. Cell growth was measured by the MTT 
assay. Percent growth stimulation was determined by comparison with control cell growth. Values shown are the mean ± SEM 
obtained from three independent experiments.
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(A-B). Effects of Hsulf-1 on EGF/HB-EGF and FGF-2 induced receptor phosphorylation and MAPK phosphorylation Figure 7
(A-B). Effects of Hsulf-1 on EGF/HB-EGF and FGF-2 induced receptor phosphorylation and MAPK phosphor-
ylation. Panc-1 pancreatic cancer cells were cultured in 1% FBS medium overnight and then incubated with 10 µg/ml of the 
indicated growth factors for 10 min. Phosphorylation of MAP kinase and receptor phosphorylation (EGFR) was determined by 
immunoblotting with antibodies specific for phospho-p44/42 MAPK and phospho-EGFR. Equal loading was determined by re-
blotting the membranes with an γ -tubulin antibody. The figure is representative of three independent experiments. (C) Hsulf-
1 attenuates FGF-2 stimulated invasion. An in vitro cell invasion assay was performed using 8 µM filters coated with 
Matrigel as described in the Material and Methods section. Panc-1 cells (1.25 × 105) were seeded onto the filters in 1% serum 
overnight, and then treated as indicated for 24 h. The values shown are the mean ± SEM obtained from three independent 
experiments.
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study a significant up-regulation of Hsulf-1 in primary
pancreatic cancer, pancreatic metastasis and CP compared
to normal pancreatic tissues was demonstrated, whereas
there was no significant difference in the expression of
other members of the sulfatase family in these tissues.
This indicates that Hsulf-1 might play a specific role in the
pathogenesis and evolution of CP and pancreatic cancer.
Normal pancreatic tissues are composed mainly of a
homogenous population of acinar cells (and a low
percentage of ductal and islet cells), whereas both CP and
pancreatic cancer tissues contain a variable amount of
desmoplastic areas, inflammatory cells, degenerating
acini, tubular complexes (and cancer cells). Thus, the
observed wide range of expression of Hsulf-1 mRNA in
both CP and pancreatic cancer tissues is most likely due to
the different individual composition of these tissues. To
confirm this hypothesis, in situ hybridization was utilized
to localize Hsulf-1 mRNA expression in normal, CP and
pancreatic cancer tissues. This analysis demonstrated that
Hsulf-1 mRNA expression was weakly present in normal
acinar cells, and at high levels in the endothelium and
smooth muscle cells of blood vessels, as well as in fibrob-
lasts and tubular complexes in CP tissues and additionally
in the malignant cells in pancreatic cancer tissues.
The observed increased levels of Hsulf-1 in pancreatic can-
cer tissues seem to be in contrast to the down-regulation
of Hsulf-1 in HCC and ovarian tumors [11,12]. However,
while in ovarian cancer markedly diminished levels were
observed in approximately 75% of the cases [11], the
Effects of Hsulf-1 on the sensitivity towards chemotherapeutic agents Figure 8
Effects of Hsulf-1 on the sensitivity towards chemotherapeutic agents. Panc-1 cells were cultured in complete 
medium and incubated in the absence (control) or presence of increasing concentrations of the indicated drugs for 48 h. Cell 
growth was measured by the MTT assay. Percent growth inhibition was determined by comparison with control cell growth. 
Values shown are the mean ± SEM obtained from three independent experiments.
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percentage was much smaller in HCCs (30%) [12], sug-
gesting that reduced Hsulf-1 expression is not universally
observed in all tumor types. It has been hypothesized that
enhanced expression of Hsulf-1 is related to c-myc ampli-
fication in HCCs [12]. It could be speculated that also in
pancreatic cancer high Hsulf-1 levels are related to c-myc
amplification [15], at least in a subset of tumors. Another
interesting aspect is the generally low Hsulf-1 expression
level in cultured cancer cell lines. Thus, Hsulf-1 expression
is absent in 71% of ovarian cancer cell lines [11], in 82%
of HCC cell lines [12], and in 50% of pancreatic cancer
cell lines (present study).
To evaluate the functional importance of Hsulf-1 in pan-
creatic cancer cells, Panc-1 cells, which do not express
Hsulf-1 at detectable levels, were stably transfected with a
Hsulf-1 expression vector. Over-expression of Hsulf-1 in
Panc-1 cells resulted in reduced anchorage-dependent and
-independent cell growth, suggesting an important
growth regulatory role of this gene in pancreatic cancer.
These tumors are characterized by enhanced expression of
a variety of growth factors and their receptors, which have
the capacity to influence different cellular functions, such
as cell proliferation, migration and angiogenesis [3,4].
Some of these growth factors are heparin-binding growth
factors, such as FGFs, VEGF and HB-EGF. We hypothe-
sized that Hsulf-1 expression would attenuate the effects
of these growth factors by desulfation of HSPGs resulting
in a growth disadvantage as suggested for other tumors
[11-13]. FGF-2 stimulated cell proliferation was attenu-
ated by the expression of Hsulf-1. Nonetheless, FGF-2 still
induced growth in Hsulf-1 expressing cells, but to a lesser
extent compared with control cells. It is conceivable that
the HSPG/FGF receptor complex can facilitate FGF-2 sign-
aling, but may not be strictly required for binding of FGF-
2 to its receptor; it only increases the affinity of the FGF-2/
FGF receptor interaction to a certain degree. Hsulf-1
expression in Panc-1 cells also partially blocked FGF-2
induced MAPK phosphorylation and invasion, further
supporting the hypothesis that Hsulf-1 interferes with
FGF-2 signaling in pancreatic cancer cells. In contrast, no
difference between Hsulf-1 expressing and control cells
was observed upon stimulation with HB-EGF – another
heparin-binding growth factor- as well as EGF and IGF-1
suggesting that these growth factors and their receptors do
not require sulfated HSPGs for effective signaling. The
observation that Hsulf-1 expression does not interfere
with HB-EGF signaling in pancreatic cancer cells is in con-
trast to recent studies in ovarian cancer cells [11], suggest-
ing cell type specific differences.
Previously, it has been shown that Hsulf-1 expression
enhances cisplatin-induced apoptosis in HCC cell lines
[12]. In the present study, we did not observe increased
sensitivity towards chemotherapeutic agents in Hsulf-1
expressing versus control cells. In contrast, Hsulf-1
expressing Panc-1 cells were more resistant to gemcitabine
than the control cells, thereby suggesting that Hsulf-1
over-expression might confer increased chemoresistance
to pancreatic cancer cells and thus provide them with a
growth advantage. However, the reason behind this effect
is currently not known and requires further analysis.
In conclusion, Hsulf-1 is up-regulated in pancreatic cancer
and chronic pancreatitis compared to normal pancreatic
tissues, mainly due to over-expression in the desmoplastic
and cancerous tissue elements. Expression of Hsulf-1 in
Panc-1 cells negatively influences growth and invasion by
attenuating FGF-2 signaling, suggesting that Hsulf-1 plays
a specific role in the pathogenesis of pancreatic cancer.
Further experimental approaches, especially in vivo stud-
ies, will help to assess in more detail the role of this
enzyme in human pancreatic cancer.
Materials and methods
Materials
DMEM, trypsin-EDTA, and penicillin-streptomycin were
purchased from Invitrogen (Mannheim, Germany); FBS
from PAN Biotech (Aidenbach, Germany); Gene screen
hybridization transfer membranes from PerkinElmer Life
Science (Boston, MA, USA); 32P CTP from Amersham
Pharmacia Biotech (Freiburg, Germany); Lipofectamine
reagent™ and TRIzol Reagent from Invitrogen (Karlsruhe,
Germany); RiboMAX™ Large Scale RNA production sys-
tem, antibiotic G-418 sulfate from Promega (Mannheim,
Gemany); Gemcitabine-Hydrochloride from Lilly (Eli
Lilly and Company Limited, Hampshire, UK); Recom-
binant human FGF-2, Recombinant human IGF-1,
Recombinant human HB-EGF from R&D systems (Wies-
baden-Nordenstadt, Germany); p-EGFR (Tyr 1173)
antibody from Santa Cruz Biotechnology (Santa Cruz,
CA, USA), p-P44/42 MAPK (Thr202/Tyr204) antibodies
from Cell Signaling Technology (Frankfurt, Germany);
EGF from Upstate Biotechnology (Hamburg, Germany);
monoclonal anti-Heparan sulfate (10-E4 epitope) from
Seikagaju Corporation (Tokyo, Japan); Labeled goat anti-
mouse IgM antibodies from Molecular Probes (Leiden,
Netherlands); Anti-c-Myc antibody from Invitrogen (Karl-
sruhe, Germany); Anti-goat IgG HRP- linked antibodies,
anti-mouse IgG HRP- linked antibodies, anti-rabbit IgG
HRP- linked antibodies and ECL immunoblotting
detection reagents from Amersham Biosciences (Freiburg,
Germany); complete mini-EDTA-free protease inhibitor
cocktail tablets from Roche (Mannheim, Germany);
DIFCO Noble agar from DIFCO Laboratories (Detroit,
MI,) All other reagents were from Sigma (Munich,
Germany).Molecular Cancer 2005, 4:14 http://www.molecular-cancer.com/content/4/1/14
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DNA array
The GeneChip® HG-U95Av2 array used in this study was
fabricated by Affymetrix Inc. (Santa Clara, CA). Poly (A)+
RNA isolation, cDNA synthesis, cRNA in vitro transcrip-
tion, product purification and fragmentation was
performed as described [16,17]. Hybridization of the frag-
mented in vitro transcription product to oligonucleotide
arrays was performed according to the manufacturer
instructions (Affymetrix Inc.).
Patients and tissues collection
31 pancreatic cancer samples were obtained from patients
(median age 62.5 years; range, 41–78 years), who under-
went pancreatic resections for pancreatic cancer at the
University Hospitals of Berne (Switzerland) and Heidel-
berg (Germany). 22 chronic pancreatitis samples were
obtained from patients who underwent resection for
chronic pancreatitis (median age 44 years range 22–66
years). 19 normal human pancreatic tissue samples were
obtained from previously healthy individuals through an
organ donor program (median age 45 years range 20–74
years). Immediately upon surgical removal, tissue sam-
ples were either snap-frozen in liquid nitrogen and then
maintained at -80°C until use (for RNA extraction) or
fixed in 5% formalin and embedded in paraffin after 24 h.
All studies were approved by the Ethics Committees of the
University of Heidelberg, and the University of Bern. Writ-
ten informed consent was obtained from all patients.
Cell culture
Pancreatic cancer cell lines were routinely grown in
DMEM medium (Panc-1 and Mia-PaCa-2) or RPMI
medium (Aspc-1, BxPc-3, Capan-1, Colo-357, SU-8686
and T3M4) supplemented with 10% fetal calf serum
(FCS), 100 U/ml penicillin, and100 µg/ml streptomycin
(complete medium). Cells were maintained at 37°C in a
humid chamber with 5% CO2 and 95% air atmosphere.
Real-time quantitative polymerase chain reaction (QRT-
PCR)
All reagents and equipment for mRNA and cDNA prepa-
ration were purchased from Roche (Roche Applied Sci-
ence, Mannheim, Germany). mRNA was prepared by
automated isolation using the MagNA Pure LC instrument
and isolation Kit I (for cells) and Kit II (for tissues). RNA
was reverse transcribed into cDNA using the 1st Strand
cDNA Synthesis Kit for RT-PCR (AMV) according to the
manufacturer's instructions. QRT-PCR was performed
with the Light Cycler Fast Start DNA SYBR Green kit as
described previously [18]. The number of specific tran-
scripts was normalized to housekeeping genes (cyclophi-
lin B and hypoxanthine guanine
phosphoribosyltransferase, HPRT), and presented as
adjusted transcripts / µl cDNA. All primers were obtained
from Search-LC (Heidelberg, Germany).
In situ hybridization
Specific human Hsulf-1 riboprobes were generated by
reverse-transcription polymerase chain reaction using the
following primer pairs: Hsulf-1: sense, 5'-ACT GTA CCA
ATC GGC CAG AG-3'; antisense, 5'-CCT CCT TGA ATG
GGT GAA GA -3'. The resulting polymerase chain reaction
products were subcloned into the pGEM-T easy vector
(Promega GmbH, Mannheim, Germany) containing pro-
moters for DNA-dependent SP6 and T7 RNA polymerases.
The authenticity of the subcloned Hsulf-1 fragment was
confirmed by sequencing (Qiagen GmbH, Hilden, Ger-
many). Plasmids were linearized using SpeI and NcoI
restriction enzymes. T7 and SP6 RNA polymerases were
used to construct sense and antisense complementary
RNA riboprobes. Biotin complementary RNA labeling was
performed using the biotin RNA labeling kit according to
the manufacturer's instructions (Roche Diagnostics, Man-
nheim, Germany). Tissue sections (3 µm) were deparaffi-
nized, rehydrated with 1× phosphate-buffered saline, and
incubated in 0.2 M/L HCl for 20 minutes at room
temperature. After rinsing the slides in 2× standard saline
citrate, sections were treated with proteinase K (Roche
Diagnostics) at a concentration of 25 µg/ml for 15 min-
utes at 37°C. After postfixation with 4% paraformalde-
hyde in phosphate-buffered saline for 5 minutes and
washing in 2× standard saline citrate, samples were
acetylated in 2.5% acetic anhydride and 1.5% trieth-
anolamine for 10 minutes. Subsequently, sections were
prehybridized at 78°C for 2 hours in 50% formamide, 4×
standard saline citrate, 2× Denhardt's reagent, and 250 µg
RNA/ml. Hybridization was performed overnight at 78°C
in 50% formamide, 4× standard saline citrate, 2× Den-
hardt's reagent, 500 µg RNA/ml, and 10% dextran sulfate.
The final concentration of the biotin-labeled probes was
0.8 ng/µl. After hybridization, excess probe was removed
by washing the slides 3 times in Dako stringent wash solu-
tion (Dako) at 78°C for 15 minutes. The samples were
then incubated with streptavidin alkaline phosphatase
conjugate (Dako) for 30 minutes at room temperature.
For the color reaction, 5-bromo-4-chloro-3-indolyl phos-
phate/nitroblue tetrazolium substrate (Dako) was used.
Stable transfection
The Hsulf-1 expression plasmid (pcDNA 3.1/myc-His)
[10] was a kindly provided by S.D. Rosen (University of
California, San Francisco). Panc-1 pancreatic cancer cells
were stably transfected with the Hsulf-1 plasmid and with
the empty control vector using the lipofectamine reagent
[7,8]. Briefly, after reaching confluence, cells were split
1:10 into selection medium (complete medium supple-
mented with 1200 µg/ml G418) and single clones were
isolated after 2–4 weeks. After expansion, cells fromeach
individual clone were screened for the expression of
Hsulf-1 by Northern blot analysis. Parental Panc-1 pan-
creatic cancer cells were also transfected with an emptyMolecular Cancer 2005, 4:14 http://www.molecular-cancer.com/content/4/1/14
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expression vector carrying the neomycin-resistance gene
as a control. Positive clones were routinely grown in selec-
tion medium.
RNA extraction and Northern Blot analysis
The pGEMT-easy vector containing the Hsulf-1 fragment
was linearized with SpeI, and a 32P -labeled riboprobe was
synthesized with the RiboMAX™ large scale RNA produc-
tion system kit using T7 polymerase and 32P CTP. Total
RNA was extracted by the single step-acid guanidinium
thiocyanate phenol chloroform method [7,8]. RNA (15
µg/lane) was size fractionated on 1.2 % agarose/1.8 M for-
maldehyde gels. Gels were stained with ethidium bromide
for verification of RNA integrity and loading equivalency.
Fractionated RNA was transferred onto Genescreen
membranes and cross linked by UV irradiation. Blots were
then prehybridized for 12 h at 65°C in 50% formamide,
1% SDS, 5 × Denhardt's, 100 µg/ml salmon sperm DNA,
50 mM Na2PO4, pH 7.4, 10% dextran, 75 mM NaCl and
5 mM EDTA. Blots were then hybridized for 24 h at 65°C
in the presence of 32P CTP labeled riboprobe, rinsed twice
with 2 × SSC and washed twice with 0.2 × SSC/2%SDS at
65°C for 20 min, respectively. All blots were exposed at -
80°C to Kodak BiomaxMS films with Kodak-intensifying
screens.
Immunoblot analysis
Cell culture monolayers were washed twice with ice-cold
PBS and lysed with lysis buffer (50 mM Tris-HCl, 100 mM
NaCl, 2 mM EDTA,1% SDS) containing one tablet of
complete mini-EDTA-free protease inhibitor cocktail (in
10 ml buffer). Protein concentration was determined by
the BCA protein assay (Pierce Chemical Co, Rockford,
IL,). Cell lysates (30 µg/lane) were separated on SDS-poly-
acrylamide gels and electroblotted onto nitrocellulose
membranes. Membranes were then incubated in blocking
solution (5% nonfat- milk in 20 mM Tris-HCl, 150 mM
NaCl, 0.1% Tween-20), followedby incubation with the
indicated antibodies at 4°C overnight. The membranes
were then washed in blocking solution and incubatedwith
HRP-conjugated secondary antibodiesfor 1 hour at room
temperature. Antibody detection was performedby an
enhanced chemiluminescence reaction.
Sulfatase assay
To assay sulfatase activity in whole cell extracts, cells were
lysed in lysis buffer (10 mM HEPES, 150 mM NaCl, 1%
NP-40, 10% glycerol, 1.0 mM PMSF, and 1 mM EGTA),
and the lysates were incubated on ice for 10 minutes. 4-
Methylumbelliferyl-sulfate was used as the substrate. Cell
lysates with 100 µg protein were diluted with SIE (250
mmol/l sucrose, 3 mmol/L imidazole, 0.1% absolute eth-
anol, pH 7.4) to a total volume of 100 µl. One hundred µl
of 1 µmol/l 4-methylumbelliferylsulfate was added to
each tube, mixed, and incubated at 37°C for 12 hours. 2
ml of stop solution (50 mM glycine, 5 mM EDTA, pH
10.4) was then added and mixed, and released 4-methyl-
umbelliferone was measured using a fluorometer (excita-
tion wavelength 360 nm, emission wavelength 460 nm).
Immunofluorescence assay
Cells were grown in complete medium overnight in 10-
well chambers, washed with PBS, fixed with 4% formalde-
hyde/PBS for 20 min at room temperature (RT), incu-
bated in ice-cold methanol for 5 min (RT) and
subsequently in acetone for 2 min (RT). Cells were incu-
bated overnight with an anti-mouse antibody that recog-
nizes negative heparan sulfate that contains the N-sulfated
glusamine residue (10E-4 mAb; 1:30 dilution) (Seikagaku
Corporation Tokyo, Japan). Cells were then washed 3
times with PBS, incubated with Alexa Fluor labeled goat
anti-mouse IgM antibodies (Molecular Probes, Leiden,
Netherlands) for 1 hour at room temperature, washed
with PBS and mounted with DAPI and anti-fading
medium (Gel/mountTM, Abcam, Cambridgeshire, UK).
Confocal microscopic analysis was performed using the
Spectral Confocal Microscope Leica TCS SL (Leica Micro-
systems GmbH, Heidelberg, Germany).
Proliferation assay
Anchorage-dependent cell growth was determined by the
3-(4,5-methylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) colorimeric growth assay [7]. Briefly, 2,000
cells/well were plated in 96-well plates and cultured for up
to 7 days. Each day cell growth was determined by adding
MTT solution (50 µg /well) for 4 hours. Cellular MTT was
solubilized withacidic isopropanol and optical density
was measured at 570 nm. The doubling time was calcu-
lated for the exponential growth phase. To measure and
calculate the GI50 of the chemotherapeutic agent (the con-
centration that causes 50% cell growth inhibition), graded
concentrations of drugs were added to triplicate wells and
GI50 was calculated using the formula 100 x (T-T0)/(C-T0)
= 50, where T is the optical density of the test well after 48
hours period of exposure to drugs, T0 is the optical density
at time zero, and C is the control optical density after 48
hours [19]. All experiments were performed in triplicate.
Soft agar assay
Cells (1 × 103/well) were suspended in 3 ml of 0.3% Difco
Noble agar supplemented with complete culture medium.
This suspension was layered over 1.5 ml of 0.5% agar-
medium base layer in 12-well plates. After 14 days, cells
were stained with MTT (400 µg/well) for 24 h and colo-
nies larger than 0.05 mm were counted.
Invasion assay
8  µm filters were coated with Matrigel and placed in
chambers. Cells (1.25 × 104) cells were cultured in DMEM
medium containing 1% FBS overnight. FGF-2 was addedPublish with BioMed Central    and   every 
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to the top chambers. After a subsequent 24 h incubation
at 37°C, non-invaded cells were scraped off, and the cells
that migrated to the lower surface of the filter inserts were
fixed with 25% acetic acid and 75% methanol for 10 min
and stained with 1% Toluidine blue in 1% sodium borate
solution. The invasion index was expressed as the ratio of
the percent invasion of the treated cells over the percent
invasion of the control cells.
Statistical analysis
Results were expressed as mean ± SEM, unless indicated
otherwise. For statistical analysis, the Student's t test was
used. Significance was defined as p < 0.05.
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